Global T-cell Lymphoma Market to Grow by $768.07 Million During 2022-2026 – ResearchAndMarkets.com

Global T-cell Lymphoma Market to Grow by $768.07 Million During 2022-2026 – ResearchAndMarkets.com




Global T-cell Lymphoma Market to Grow by $768.07 Million During 2022-2026 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global T-cell lymphoma Market 2022-2026” report has been added to ResearchAndMarkets.com’s offering.

The T-cell lymphoma market is poised to grow by $768.07 mn during 2022-2026, accelerating at a CAGR of 8.21% during the forecast period. The report on the T-cell lymphoma market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis of the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the growing geriatric population, increasing approval of therapeutics for patients with relapsed or refractory T-cell lymphoma, and increasing incidence of T-cell lymphoma.

The T-cell lymphoma market analysis includes the type segment and geographic landscape.

The T-cell lymphoma market is segmented as below:

By Type

  • Peripheral T-cell lymphomas
  • T-cell lymphoblastic lymphoma

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)

This study identifies technological advancements as one of the prime reasons driving the T-cell lymphoma market growth during the next few years. Also, increasing patient support programs and strategic alliances will lead to sizable demand in the market.

The report on the T-cell lymphoma market covers the following areas:

  • T-cell lymphoma market sizing
  • T-cell lymphoma market forecast
  • T-cell lymphoma market industry analysis

Key Topics Covered:

1 Executive Summary

2 Market Landscape

3 Market Sizing

4 Five Forces Analysis

5 Market Segmentation by Type

6 Customer Landscape

7 Geographic Landscape

8 Drivers, Challenges, and Trends

9 Vendor Landscape

10 Vendor Analysis

11 Appendix

Companies Mentioned

  • AbbVie Inc.
  • Accredo Health Group Inc.
  • AstraZeneca Plc
  • Autolus Therapeutics Plc
  • Baxter International Inc.
  • Biogen Inc.
  • Bristol Myers Squibb Co.
  • Eli Lilly and Co.
  • F. Hoffmann La Roche Ltd.
  • Genmab AS
  • GSK Plc
  • H. Lee Moffitt Cancer Center and Research Institute Inc.
  • Johnson and Johnson
  • Macopharma SA
  • Merck and Co. Inc.
  • Mundipharma International Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • TYME Inc.

For more information about this report visit https://www.researchandmarkets.com/r/3hjpvw

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900